<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255512</url>
  </required_header>
  <id_info>
    <org_study_id>18582</org_study_id>
    <secondary_id>2016-005178-36</secondary_id>
    <nct_id>NCT03255512</nct_id>
  </id_info>
  <brief_title>Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients</brief_title>
  <acronym>VISOR</acronym>
  <official_title>Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study to Investigate Safety, Tolerability and Blood Pressure of 2.5 mg, 5.0 mg and 10 mg Vericiguat Each Given Over 14 ± 3 Days Together With Isosorbite Mononitrate (ISMN) 60 mg Extended Release Formulation After a Pretreatment Phase (ISMN-starting Dose: 30 mg) in Stable Coronary Artery Disease (CAD) Patients With or Without Heart Failure Aged 30 to 80 Years - Vericiguat ISOsoRbite Mononitrate Interaction (VISOR) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to investigate the pharmacodynamic drug-drug interaction as well as
      the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable
      coronary artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Regular measurements of blood pressure after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Regular measurements heart rate after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Vericiguat + isosorbite mononitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of vericiguat and isosorbite mononitrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + isosorbite mononitrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of (vericiguat) matching placebo and isosorbite mononitrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vericiguat (BAY1021189) + isosorbite mononitrate</intervention_name>
    <description>ISMN up-titration with 30 mg / 60 mg, about 7 days each, prior to start of vericiguat administration
Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be up-titrated to 5 mg and to 10 mg:
2.5 mg vericiguat for about 14 days followed by 5 mg vericiguat for about 14 days followed by 10 mg vericiguat for about 14 days
60 mg ISMN od on each day of vericiguat administration, taken 1 hour prior to vericiguat (in-house days) or together with vericiguat (out-patient days)</description>
    <arm_group_label>Vericiguat + isosorbite mononitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + isosorbite mononitrate (ISMN)</intervention_name>
    <description>ISMN up-titration with 30 mg / 60 mg, about 7 days each, prior to start of placebo administration
Placebo for about 14 days, once daily
60 mg ISMN od on each day of placebo administration, taken 1 hour prior to placebo (in-house days) or together with placebo (out-patient days)</description>
    <arm_group_label>Placebo + isosorbite mononitrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with stable CAD defined by

          -  coronary artery stenosis in any of the 3 main coronary vessels &gt; 50% documented by
             coronary angiography within last 36 months

          -  or history of myocardial infarction

          -  Age: 30 to 80 years (inclusive) at the first screening examination

          -  Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg / m²

        Exclusion Criteria:

          -  Intervention e.g. revascularization by percutaneous coronary intervention (PCI) and/or
             coronary artery bypass graft (CABG) during the last 3 months

          -  Progressive angina with symptoms of worsening of angina within the &lt; 3 months prior to
             the first screening examination

          -  History of recent (&lt; 6 months prior to the first screening examination) myocardial
             infarction or unstable angina

          -  Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months
             prior to the first screening examination or patients with stroke at more than 3 months
             prior to the first screening examination with significant residual neurologic
             involvement

          -  Insulin dependent diabetes mellitus

          -  Clinically relevant cardiac ischemia at screening

          -  Clinical significant persistent ischemia, which should be ruled out by clinical
             judgment of the investigator, based on medical history, available clinical data e.g.
             past angiograms or preexisting or current exercise testing with any imaging technique
             (e.g. dobutamine stress echocardiography, adenosine or dobutamine stress cardiac
             magnetic resonance imaging (CMR), scinthigraphy or exercise ECG)

          -  Atrial fibrillation, pacemaker, defibrillator, atrial ventricular (AV)-block II and
             III

          -  Systolic blood pressure below 110 or above 160 mmHg at first screening visit

          -  Diastolic blood pressure above 100 mmHg at first screening visit

          -  Heart rate below 50 or above 100 beats / min (taken from ECG measurement) at first
             screening visit

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m*2 at first screening
             visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsherzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Württemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SocraTec R&amp;D Clinical Ward</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

